Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces positive mCRC data

Amgen announces positive mCRC data

7th August 2009

Amgen has announced positive results from a phase III trial into Vectibix (panitumumab) as a therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC).

The drug was administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) and was found to significantly prolong progression-free survival, in comparison to FOLFOX alone, as a first-line treatment.

Roger Perlmutter, executive vice-president of research and development at Amgen, said the results represent an “important advance” for people with mCRC.

He also noted that the study was amended to analyse patient outcomes with respect to the absence or presence of activating mutations in KRAS in the tumour itself, having originally been intended to compare the treatment effect in the overall population.

“Our study underscores the importance of KRAS status in identifying the appropriate patient population to be treated with Vectibix, consistent with worldwide labelling,” he added.

Mr Perlmutter concluded by noting that Amgen believes Vectibix should not be administered to patients who have tumours containing activating KRAS mutations.

Last month, Amgen announced a partnership with GlaxoSmithKline to commercialise its monoclonal antibody denosumab for postmenopausal osteoporosis in Europe.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.